SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

11 Nov 2022 Evaluate
A decrease in the sales to Rs. 1748.35 millions was observed for the quarter ended September 2022. The sales stood at Rs. 1941.39 millions during the similar quarter previous year.The Net proft of the company remain more or less same to Rs. 202.12  millions from Rs. 233.35 millions ,decline by -13.38%.Operating Profit reported a sharp decline to 334.31 millions from 361.34 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202209 202109 % Var 202209 202109 % Var 202203 202103 % Var
Sales 1748.35 1941.39 -9.94 3401.11 4448.97 -23.55 7791.56 4876.99 59.76
Other Income 8.18 3.05 168.20 11.93 15.33 -22.18 31.04 37.33 -16.85
PBIDT 334.31 361.34 -7.48 669.85 830.10 -19.30 1488.20 876.53 69.78
Interest 16.06 15.49 3.68 25.14 27.58 -8.85 48.47 136.33 -64.45
PBDT 318.25 345.85 -7.98 644.71 802.52 -19.66 1439.73 740.20 94.51
Depreciation 45.64 41.97 8.74 89.29 83.23 7.28 171.34 163.08 5.06
PBT 272.61 303.88 -10.29 555.42 719.29 -22.78 1268.39 577.12 119.78
TAX 70.49 70.53 -0.06 142.78 173.87 -17.88 309.98 134.80 129.96
Deferred Tax -6.51 -6.17 5.51 -7.82 -8.43 -7.24 -11.52 20.11 -157.28
PAT 202.12 233.35 -13.38 412.64 545.42 -24.34 958.41 442.32 116.68
Equity 96.94 96.94 0.00 96.94 96.95 -0.01 96.94 96.94 0.00
PBIDTM(%) 19.12 18.61 2.74 19.70 18.66 5.56 19.10 17.97 6.27

Gufic Biosciences Share Price

301.30 -1.35 (-0.45%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×